Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Senti Biosciences, Inc. - Common Stock (NQ:SNTI)

1.610 -0.030 (-1.83%)
Streaming Delayed Price Updated: 1:52 PM EDT, Aug 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Senti Biosciences, Inc. - Common Stock

< Previous 1 2 Next >
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
From Pomerantz LLP
Via GlobeNewswire
SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. – SNTI
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
From Pomerantz LLP
Via GlobeNewswire
Senti Bio Announces Reverse Stock Split
Shares expected to begin trading on split-adjusted basis on July 18, 2024 
From Senti Biosciences, Inc.
Via GlobeNewswire
Complete Solaria, Senti, and POET: 3 High Volume Penny Stocks
Penny stocks are risky, but follow the money to find winners. Stocks with significant volume spikes may have what it takes for higher share prices. 
Via MarketBeat
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
$8M grant supports ongoing Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia 
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio to Participate in Upcoming Conferences
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio to Participate in Upcoming Investor Conferences
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophages 
From Senti Biosciences, Inc.
Via GlobeNewswire
Senti Bio Announces First Quarter 2023 Results and Pipeline Updates
From Senti Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.